Stock listing

Lang & Schwarz:A140E0 Regenxbio Inc. Aktie

German listing (Lang & Schwarz) of Regenxbio Inc. · home listing NASDAQ:RGNX

Follow Regenxbio Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:RGNX

$7.16 USD -0.10 (-1.4%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:RGNX

Past year -34.1% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$6.86 – $7.30 USDNov 20, 2026
Volume
1.05M sharesNov 20, 2026
Market cap
$473.4M USDAt the close on Nov 20, 2026 · price × 66.12M shares outstanding
52-week range
$5.46 – $16.19 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$10.96M USDMedian day 1.19M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Regenxbio Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:RGNX · Home$7.16 USD-0.10 (-1.4%)1,054,138$7.00$7.30$6.86$7.26Close on Nov 20, 2026
Frankfurt:RB0€6.412 EUR-0.23 (-3.5%)—€6.412€6.412€6.412€6.642Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:RGNX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$7.16-0.10-1.4%$7.00$7.30$6.861,054,138
$7.26+0.02+0.3%$7.23$7.56$7.12700,292
$7.24-0.08-1.1%$7.35$7.493$6.84963,087
$7.32-0.32-4.2%$7.59$7.815$7.30908,089
$7.64-0.39-4.9%$8.02$8.02$7.39716,119
$8.03-0.44-5.2%$8.23$8.33$7.941,283,919
$8.47+0.78+10.1%$7.62$8.88$7.621,845,043
$7.69-0.38-4.7%$8.06$8.14$7.281,084,412
$8.07+0.45+5.9%$7.77$8.23$7.472,173,999
$7.62+0.24+3.3%$7.33$7.87$7.331,186,481
$7.38-0.33-4.3%$7.20$7.68$7.151,677,167
$7.71+0.08+1.0%$7.72$7.96$7.4751,135,429
$7.63+0.47+6.6%$7.29$7.645$7.266854,953
$7.16-0.04-0.6%$7.27$7.459$7.041,029,332
$7.20-0.21-2.8%$7.38$7.535$7.001,061,611
$7.41+0.17+2.3%$7.36$7.625$7.211,033,352
$7.24+0.64+9.7%$6.52$7.285$6.5051,998,860
$6.60+0.02+0.3%$6.54$6.78$6.4591,219,377
$6.58-0.10-1.5%$6.83$6.89$6.4851,137,663
$6.68-0.49-6.8%$7.03$7.08$6.6281,441,500
$7.170.000.0%$7.11$7.305$6.981,132,500
$7.17-0.23-3.1%$7.42$7.47$7.15945,300
$7.40+0.25+3.5%$7.15$7.58$7.061,315,100
$7.15+0.225+3.2%$6.98$7.265$6.951,298,000
$6.925-0.235-3.3%$7.14$7.18$6.8751,210,200
$7.16+0.28+4.1%$6.88$7.28$6.831,228,300
$6.88-0.38-5.2%$7.12$7.24$6.801,564,900
$7.26-0.51-6.6%$7.66$7.72$7.111,378,400
$7.77-0.30-3.7%$8.12$8.29$7.742,033,600
$8.07-0.02-0.2%$8.03$8.275$7.95859,100
$8.09+0.495+6.5%$7.50$8.31$7.442,258,800
$7.595+0.145+1.9%$7.31$7.73$7.201,004,900
$7.45-0.31-4.0%$7.79$7.84$7.331,164,100
$7.76+0.33+4.4%$7.80$8.16$7.572,349,800
$7.43+0.01+0.1%$7.58$7.62$7.361,036,600
$7.42-0.11-1.5%$7.52$7.736$7.301,705,100
$7.53+0.08+1.1%$7.49$7.86$7.351,788,600
$7.45-0.02-0.3%$7.41$7.64$7.332,095,900
$7.47+0.07+0.9%$7.30$7.495$7.171,325,800
$7.40+0.16+2.2%$7.53$7.675$7.1651,276,500
$7.24-0.26-3.5%$7.45$7.46$7.121,509,200
$7.50-0.65-8.0%$8.13$8.145$7.401,112,900
$8.15+0.27+3.4%$8.03$8.25$7.9041,202,500
$7.88-0.15-1.9%$8.24$8.313$7.761,115,700
$8.03-0.185-2.3%$8.22$8.331$8.003,374,800
$8.215+0.235+2.9%$8.34$8.56$8.021,808,100
$7.98+0.035+0.4%$7.93$7.99$7.6361,231,600
$7.945-0.745-8.6%$8.69$8.75$7.781,426,600
$8.69+0.16+1.9%$8.58$8.728$8.49858,400
$8.53-0.03-0.4%$8.69$8.82$8.391,029,100
$8.56-0.17-1.9%$8.63$8.79$8.471,172,100
$8.73-0.03-0.3%$8.70$9.025$8.621,407,400
$8.76-0.18-2.0%$8.95$8.95$8.60998,700
$8.94-0.26-2.8%$9.09$9.215$8.861,069,100
$9.20-0.40-4.2%$9.56$9.56$9.00839,200
$9.60+0.28+3.0%$9.34$9.708$9.20866,300
$9.32-0.18-1.9%$9.38$9.616$9.28783,700
$9.50-0.16-1.7%$9.50$9.68$9.091,611,400
$9.66+0.29+3.1%$10.00$10.10$9.2121,752,500
$9.37-0.01-0.1%$9.35$9.46$9.04916,600
$9.38+0.47+5.3%$8.85$9.43$8.611,160,000
$8.91+0.855+10.6%$8.14$8.99$8.131,756,781
$8.055-2.665-24.9%$8.29$8.64$7.775,446,547
$10.72-0.34-3.1%$11.14$11.16$10.491,005,500
$11.06-0.96-8.0%$11.98$12.08$11.03947,300
Ticker
Lang & Schwarz:A140E0
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Lang & Schwarz
Currency
EUR

What changed lately

Latest news

All Regenxbio Inc. news

Regenxbio Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
26 in the last 12 months · 223 in all · newest Nov 5, 2026 · oldest 2019
Calls
25 calls with a replay · 25 with a transcript · latest Nov 5, 2026
Decks
22 decks · latest September 2026

Where Regenxbio Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:RGNX · Home listingNASDAQUnited StatesUSD
gettex:RB0gettexGermanyEUR
LS Exchange:A140E0LS ExchangeGermanyEUR
Tradegate:RB0TradegateGermanyEUR
Lang & Schwarz:A140E0 · This pageLang & SchwarzGermanyEUR
Frankfurt:RB0FrankfurtGermanyEUR
BOATS:RGNXBOATSUnited StatesUSD
Munich:RB0MunichGermanyEUR
Dusseldorf:RB0DusseldorfGermanyEUR
Stuttgart:RB0StuttgartGermanyEUR

Valuation

EV/sales 1.9× against a median of 13.1×: the lowest of 4 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$289.0M USD
P/E
Loss
EV/sales
1.9×
EV/EBITDA
Negative EBITDA
Price/book
3.2×
Gross margin
87.5%
Operating margin
−95.7%
Net margin
−113.9%
Debt to equity
0.5×
Beta vs S&P 500
1.60

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Regenxbio Inc. · NASDAQ:RGNXUS$473.4MUS$289.0Mn/a1.9×n/a3.2×−113.9%0.5×1.60
Steminent Biotherapeutics, Inc. · TPEX:7729US$496.9MUS$470.4Mn/an/an/a16.2×n/a0.0×n/a
Xuanzhu Biopharmaceutical Co., Ltd. Class H · HKEX:2575US$495.2MUS$407.1Mn/a23.2×n/a2.2×−200.8%0.0×n/a
TenNor Therapeutics Suzhou Ltd. Class H · HKEX:6872US$489.2MUS$391.6Mn/an/an/a5.0×n/a0.1×n/a
Crescent Biopharma, Inc. · NASDAQ:CBIOUS$482.9MUS$196.0Mn/a13.1×n/a1.8×−727.6%0.0×0.92
Sana Biotechnology, Inc. · NASDAQ:SANAUS$476.4MUS$408.5Mn/an/an/a2.6×n/a0.3×2.29
Monopar Therapeutics Inc. · NASDAQ:MNPRUS$467.6MUS$362.8Mn/an/an/a3.7×n/a0.0×1.18
BlossomHill Therapeutics, Inc. · NASDAQ:BLSMUS$461.2MUS$259.4Mn/an/an/a2.2×n/a0.1×n/a
Neurogene Inc. · NASDAQ:NGNEUS$458.5MUS$106.4Mn/an/an/a1.3×n/a0.0×1.47
Assembly Biosciences, Inc. · NASDAQ:ASMBUS$454.4MUS$142.3Mn/a2.1×n/a1.5×−16.6%0.0×1.00
Shattuck Labs, Inc. · NASDAQ:STTKUS$454.2MUS$260.4Mn/an/an/a2.4×n/a0.0×1.10
Median of the othersUS$472.0MUS$311.6M13.1×2.3×−200.8%0.0×1.14

Forecasts

7 strong buy · 3 buy · 1 hold · Analysts' consensus from EODHD, read Nov 22, 2026. Not 6ix's view and not investment advice.

Price target
21.40 USD · Analysts' mean
EPS, year to Dec 2026
-3.77 · 2 analysts
Revenue, year to Dec 2026
153.8M · 9 analysts

Team and board

Officers

OfficerRole
Curran M. SimpsonPresident and Chief Executive Officer, Board Member
Mitchell ChanCHIEF FINANCIAL OFFICER
Patrick J. ChristmasCHIEF LEGAL OFFICER
Dana CormackCorporate Communications
Craig MalzahnChief Technology Officer
Marianne KreinerHead of People
Olivier DanosCHIEF SCIENTIFIC OFFICER
Ram PalankiChief Commercial Officer
Steve PakolaCHIEF MEDICAL OFFICER

Board

DirectorRole
George MigauskyChairman of the Board
Alexandra GlucksmannIndependent Board Member
Allan FoxIndependent Board Member
Curran M. SimpsonPresident and Chief Executive Officer, Board Member
Daniel TasséIndependent Board Member
David StumpIndependent Board Member
Greg CiongoliIndependent Board Member
Jennifer ZacharyIndependent Board Member

Events

Calls

CallWhenStatus
REGENXBIO (NASDAQ:RGNX) Q3 2026 Earnings CallThu, Nov 05, 2026 · 8:00 AM ETReplay
REGENXBIO (NASDAQ:RGNX) Q2 2026 Earnings CallThu, Aug 06, 2026 · 8:00 AM ETReplay
REGENXBIO (NASDAQ:RGNX) Q1 2026 Earnings CallThu, May 14, 2026 · 8:00 AM ETReplay
REGENXBIO (NASDAQ:RGNX) Q4 2025 Earnings CallThu, Mar 05, 2026 · 8:00 AM ETReplay
REGENXBIO (NASDAQ:RGNX) Q3 2025 Earnings CallThu, Nov 06, 2025 · 8:00 AM ETReplay
REGENXBIO (NASDAQ:RGNX) Q2 2025 Earnings CallThu, Aug 07, 2025 · 8:00 AM ETReplay
REGENXBIO (NASDAQ:RGNX) Q1 2025 Earnings CallMon, May 12, 2025 · 4:30 PM ETReplay
REGENXBIO (NASDAQ:RGNX) Q4 2024 Earnings CallThu, Mar 13, 2025 · 4:30 PM ETReplay
REGENXBIO (NASDAQ:RGNX) Q3 2024 Earnings CallWed, Nov 06, 2024 · 4:30 PM ETReplay
REGENXBIO (NASDAQ:RGNX) Q2 2024 Earnings CallThu, Aug 01, 2024 · 4:30 PM ETReplay
All 25 calls
CallWhenStatus
REGENXBIO (NASDAQ:RGNX) Q1 2024 Earnings CallWed, May 08, 2024 · 4:30 PM ETReplay
REGENXBIO (NASDAQ:RGNX) Q4 2023 Earnings CallTue, Feb 27, 2024 · 4:30 PM ETReplay
REGENXBIO (NASDAQ:RGNX) Q3 2023 Earnings CallWed, Nov 08, 2023 · 4:30 PM ETReplay
REGENXBIO (NASDAQ:RGNX) Q2 2023 Earnings CallWed, Aug 02, 2023 · 4:30 PM ETReplay
REGENXBIO (NASDAQ:RGNX) Q1 2023 Earnings CallWed, May 03, 2023 · 4:30 PM ETReplay
REGENXBIO (NASDAQ:RGNX) Q4 2022 Earnings CallTue, Feb 28, 2023 · 4:30 PM ETReplay
REGENXBIO (NASDAQ:RGNX) Q3 2022 Earnings CallThu, Nov 03, 2022 · 8:30 AM ETReplay
REGENXBIO (NASDAQ:RGNX) Q2 2022 Earnings CallWed, Aug 03, 2022 · 4:30 PM ETReplay
REGENXBIO (NASDAQ:RGNX) Q1 2022 Earnings CallWed, May 04, 2022 · 4:30 PM ETReplay
REGENXBIO (NASDAQ:RGNX) Q4 2021 Earnings CallTue, Mar 01, 2022 · 4:30 PM ETReplay
REGENXBIO (NASDAQ:RGNX) Q3 2021 Earnings CallTue, Nov 02, 2021 · 4:30 PM ETReplay
REGENXBIO (NASDAQ:RGNX) Q2 2021 Earnings CallMon, Aug 09, 2021 · 4:30 PM ETReplay
REGENXBIO (NASDAQ:RGNX) Q1 2021 Earnings CallWed, May 05, 2021 · 4:30 PM ETReplay
REGENXBIO (NASDAQ:RGNX) Q4 2020 Earnings CallMon, Mar 01, 2021 · 4:30 PM ETReplay
REGENXBIO (NASDAQ:RGNX) Q3 2020 Earnings CallWed, Nov 04, 2020 · 4:30 PM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 5, 2026 · Before open−4.3%
Q2 2026Aug 6, 2026 · Before open+7.4%
Q1 2026May 14, 2026 · Before open−37.8%
Q4 2025Mar 5, 2026−5.4%
Q3 2025Nov 6, 2025 · Before open−3.8%
Q2 2025Aug 7, 2025 · Before open−4.0%
Q1 2025May 12, 2025 · After close+2.6%
Q4 2024Feb 25, 2025 · Before open−3.0%
Q3 2024Nov 6, 2024 · After close+18.7%
Q2 2024Aug 1, 2024 · After close−2.0%
All 20 quarters
QuarterResultsShare move
Q1 2024May 8, 2024 · After close−5.9%
Q4 2023Feb 27, 2024 · After close−0.6%
Q3 2023Nov 8, 2023 · After close+2.4%
Q2 2023Aug 2, 2023 · After close−7.5%
Q1 2023May 3, 2023 · After close−1.6%
Q4 2022Feb 28, 2023 · After close+8.5%
Q3 2022Nov 3, 2022 · Before open−13.2%
Q2 2022Aug 3, 2022 · After close+2.2%
Q1 2022May 4, 2022 · After close−14.9%
Q4 2021Mar 1, 2022 · After close+10.1%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck40 slidesSeptember 2026
American Society of Retina Specialists (ASRS) 2026Conference10 slidesJuly 2026
Q4 2025 Earnings PresentationEarnings23 slidesMar 5, 2026
AAO 2025Conference23 slidesOct 17, 2025
World Muscle Society Annual Congress 2025Conference7 slidesOctober 2025
ICIEM 2025Conference17 slidesSep 5, 2025
Q2 2025 Earnings PresentationEarnings13 slidesAug 7, 2025
AAN 2025Conference12 slides2025
Technical Presentation (October 2024)Technical17 slidesOct 19, 2024
ASGCT 2024Conference12 slidesMay 11, 2024
All 22 decks
DeckKindSlidesDate
SSIEM 2023Conference16 slidesAug 30, 2023
SSIEM 2023Conference14 slidesAug 30, 2023
ASRS 2023Conference13 slidesJul 30, 2023
WORLDSymposium 2023Conference15 slidesMarch 2023
WORLDSymposium 2023Conference14 slidesFeb 24, 2023
Technical Presentation (October 2022)Technical19 slidesOct 3, 2022
AAO 2022Conference16 slides2022
WORLDSymposium 2021Conference17 slidesFeb 11, 2021
AAO Retina Subspecialty Days 2019Conference24 slidesOct 15, 2019
Technical Presentation (October 2018)Technical18 slidesOct 29, 2018
Q2 2018 Earnings PresentationEarnings26 slidesAug 8, 2018
Investor Presentation (September 2016)Investor deck29 slidesSep 12, 2016

Open Decks

Financings

RaiseDate
Public offering of common stock and pre-funded warrants
Closed: US$108M raised · US$9 a share · Morgan Stanley +3
Dealers: Morgan Stanley (co-lead), J.P. Morgan (co-lead), Leerink Partners (co-lead), Mizuho (co-lead)
Use of proceeds: Extend cash runway into Q4 2027 and support the planned AFFINITY RISE ex-U.S. randomized-controlled trial of RGX-202 in 1H 2027
Aug 6, 2026
Limited recourse royalty bond with warrants
Tranche closed: US$150M raised · Warrants at US$14.92
Buyers: Healthcare Royalty (HCRx) (up to $250 million bond; $150 million funded at closing, plus warrants for up to 268,096 shares)
Use of proceeds: Extend cash runway into early 2027 and fund late-stage activities and commercial preparations
May 19, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$22.00 a share on Sep 16, 2015.

Price
US$22.00 a share
Shares offered
6,300,000 shares of common stock
Offering size
US$138.6 million
Underwriters' option
Up to 945,000 more shares
Underwriters
MORGAN STANLEY, BofA MERRILL LYNCH, PIPER JAFFRAY, CHARDAN CAPITAL MARKETS, LLC · In the order on the cover
Shares delivered
On or about Sep 22, 2015

Steps

StepWhen
Draft sent to the SEC in confidenceJul 1, 2015
Filed publiclyAug 17, 2015
Amended 3 timesNewest Sep 16, 2015
Shares registered with an exchangeSep 9, 2015
Declared effective by the SECSep 16, 2015
Final prospectus, with the priceSep 17, 2015

Open IPO · From the cover of the final prospectus (424B4) filed Sep 17, 2015

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue170.4M83.3M90.2M112.7M470.3M154.6M35.2M218.5M10.4M4.59M
Cost of revenue20.3M33.6M37.2M54.5M51.8M35.7M8.24M9.64M1.71M98.0K
Gross profit150.1M49.8M53.0M58.2M418.5M118.9M27.0M208.9M8.68M3.63M
Research and development228.3M208.5M232.3M242.5M181.4M166.3M124.2M83.9M57.2M45.5M
Selling, general and administrative82.9M76.6M88.5M85.3M79.3M63.8M51.8M36.9M27.2M23.6M
Operating income-161.2M-233.3M-268.1M-262.9M160.0M-119.2M-149.0M88.1M-75.9M-65.3M
Depreciation and amortization15.6M16.2M17.3M12.9M9.56M8.41M7.15M3.98M2.69M544.0K
EBITDA-145.6M-217.1M-250.8M-250.0M169.5M-110.8M-141.8M92.1M-73.2M-64.8M
Interest expense45.0M12.7M6.86M23.3M26.3M771.0K107.2M000
Income before tax-193.9M-227.1M-263.6M-280.4M141.2M-106.0M-97.5M104.1M-73.2M-63.4M
Income tax00-152.0K-84.0K13.4M5.24M-2.75M4.18M0-435.0K
Net income-193.9M-227.1M-263.5M-280.3M127.8M-111.3M-94.7M99.9M-73.2M-63.0M
Earnings per share, basic-3.76-4.59-6.02-6.503.01-2.98-2.582.99-2.45-2.38
Earnings per share, diluted-3.76-4.59-6.02-6.502.91-2.98-2.582.73-2.45-2.38

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents34.5M57.5M34.5M97.0M345.2M338.4M69.5M75.6M46.7M24.8M
Short-term investments195.6M177.2M240.7M267.7M112.2M137.3M226.7M244.2M114.1M64.7M
Receivables26.4M20.5M24.8M28.1M32.4M43.0M38.1M8.59M473.0K1.03M
Inventory13.9M18.8M10.5M6.47M5.73M5.33M1.77M
Current assets281.3M278.0M335.0M416.0M518.8M531.2M345.0M337.9M168.0M93.4M
Property, plant and equipment104.9M117.6M132.1M141.7M131.5M56.5M29.0M28.7M14.0M9.32M
Goodwill00
Total assets453.0M466.0M574.0M833.3M1.11B708.2M497.9M543.8M198.7M172.7M
Accounts payable21.4M22.8M22.8M27.2M11.4M10.6M6.41M4.41M4.83M1.54M
Current liabilities118.1M103.2M130.3M130.4M130.5M81.4M33.7M22.2M14.4M9.67M
Long-term debt00
Total debt260.5M82.0M89.3M94.8M86.7M72.7M11.3M5.85M
Total liabilities350.3M206.3M262.2M317.1M349.6M330.4M47.7M35.0M15.6M11.0M
Shareholders' equity102.7M259.7M311.7M516.2M764.3M377.8M450.2M508.8M183.0M161.7M
Shares outstanding50.9M49.5M44.0M43.3M42.8M37.5M37.0M36.1M31.3M26.5M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-124.0M-173.1M-218.4M-207.5M218.9M-54.1M-107.7M104.6M-58.0M-48.6M
Capital spending-2.41M-2.44M-9.96M-30.7M-84.2M-26.9M-11.7M-13.3M-7.16M-8.15M
Free cash flow-126.4M-175.6M-228.4M-238.2M134.7M-80.9M-119.4M91.4M-65.2M-56.7M
Cash from investing-15.9M103.4M190.9M-11.9M-406.6M122.8M93.6M-279.4M-4.79M19.4M
Cash from financing116.8M92.7M-35.0M-28.8M195.3M200.2M8.38M204.4M84.6M119.0K
Dividends paid00
Share buybacks1.05M1.19M-419.0K-284.0K-2.00K1.80M1.31M847.0K556.0K179.0K
Change in cash-23.1M23.0M-62.4M-248.3M7.48M268.9M-5.77M29.7M21.8M-29.1M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeNov 10, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
4 · Change in ownershipNov 3, 2026Insider tradeSEC
4 · Change in ownershipNov 3, 2026Insider tradeSEC
4 · Change in ownershipNov 3, 2026Insider tradeSEC
4 · Change in ownershipNov 3, 2026Insider tradeSEC
8-K · Current reportOct 16, 2026Management or board changeSEC
SCHEDULE 13G · Big-stake noticeOct 13, 2026Big-stake noticeSEC
8-K · Current reportSep 23, 2026Material contractSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipSep 3, 2026Insider tradeSEC
4 · Change in ownershipSep 3, 2026Insider tradeSEC
4 · Change in ownershipAug 27, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 27, 2026Insider tradeSEC
8-K · Current reportAug 25, 2026Management or board changeSEC
8-K · Current reportAug 24, 2026Current reportSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
8-K · Current reportAug 6, 2026ResultsSEC
4 · Change in ownershipAug 4, 2026Insider tradeSEC
4 · Change in ownershipAug 4, 2026Insider tradeSEC
8-K · Current reportJul 20, 2026Current reportSEC
424B5 · ProspectusJul 17, 2026Offer documentSEC
FWP · Free writing prospectusJul 16, 2026Offer documentSEC
424B5 · ProspectusJul 16, 2026Offer documentSEC
4 · Change in ownershipJul 6, 2026Insider tradeSEC
4 · Change in ownershipJul 6, 2026Insider tradeSEC
SC TO-I/AJul 6, 2026Acquisition or disposalSEC
4 · Change in ownershipJul 1, 2026Insider tradeSEC
144 · Notice of proposed saleJul 1, 2026Other filingsSEC
SC TO-I/AJul 1, 2026Acquisition or disposalSEC
8-K · Current reportJun 29, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJun 4, 2026Big-stake noticeSEC
SC TO-IJun 3, 2026Acquisition or disposalSEC
8-K · Current reportJun 3, 2026Meeting outcomeSEC
4 · Change in ownershipJun 2, 2026Insider tradeSEC
4 · Change in ownershipJun 2, 2026Insider tradeSEC
4 · Change in ownershipJun 2, 2026Insider tradeSEC
4 · Change in ownershipJun 2, 2026Insider tradeSEC
4 · Change in ownershipJun 2, 2026Insider tradeSEC
4 · Change in ownershipJun 2, 2026Insider tradeSEC
4 · Change in ownershipJun 2, 2026Insider tradeSEC
4 · Change in ownershipJun 2, 2026Insider tradeSEC
4 · Change in ownershipJun 2, 2026Insider tradeSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
8-K · Current reportMay 14, 2026ResultsSEC
4 · Change in ownershipMay 13, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeMay 12, 2026Big-stake noticeSEC
144 · Notice of proposed saleMay 11, 2026Other filingsSEC
ARS · Annual report to shareholdersApr 14, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 14, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 14, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 3, 2026Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 27, 2026Big-stake noticeSEC
8-K · Current reportMar 20, 2026Material contractSEC
4 · Change in ownershipMar 12, 2026Insider tradeSEC
144 · Notice of proposed saleMar 10, 2026Other filingsSEC
10-K · Annual reportMar 5, 2026Annual reportSEC
8-K · Current reportMar 5, 2026ResultsSEC
424B5 · ProspectusFeb 12, 2026Offer documentSEC
8-K · Current reportFeb 9, 2026Current reportSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
4 · Change in ownershipJan 29, 2026Insider tradeSEC
8-K · Current reportJan 28, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 21, 2026Big-stake noticeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
EFFECT · Notice that a registration is effectiveDec 15, 2025Other filingsSEC
CORRESP · Letter to the SECDec 9, 2025Other filingsSEC
S-3 · Registration statementNov 26, 2025Offer documentSEC
8-K · Current reportNov 6, 2025ResultsSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
4 · Change in ownershipOct 10, 2025Insider tradeSEC
144 · Notice of proposed saleOct 9, 2025Other filingsSEC
4 · Change in ownershipOct 1, 2025Insider tradeSEC
4 · Change in ownershipSep 12, 2025Insider tradeSEC
144 · Notice of proposed saleSep 10, 2025Other filingsSEC
4 · Change in ownershipSep 3, 2025Insider tradeSEC
4 · Change in ownershipSep 3, 2025Insider tradeSEC
8-K · Current reportAug 18, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025ResultsSEC
4 · Change in ownershipAug 4, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJul 15, 2025Big-stake noticeSEC
4 · Change in ownershipJul 3, 2025Insider tradeSEC
EFFECT · Notice that a registration is effectiveJun 26, 2025Other filingsSEC
424B3 · ProspectusJun 25, 2025Offer documentSEC
CORRESP · Letter to the SECJun 23, 2025Other filingsSEC
UPLOAD · Letter from the SECJun 20, 2025Other filingsSEC
S-3 · Registration statementJun 13, 2025Offer documentSEC
S-8 · Registration statement for employee plansJun 13, 2025Offer documentSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
8-K · Current reportJun 3, 2025Meeting outcomeSEC
8-K · Current reportMay 19, 2025Material contractSEC
4 · Change in ownershipMay 14, 2025Insider tradeSEC
144 · Notice of proposed saleMay 12, 2025Other filingsSEC
10-Q · Quarterly reportMay 12, 2025Quarterly reportSEC
8-K · Current reportMay 12, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 24, 2025Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveApr 15, 2025Other filingsSEC
ARS · Annual report to shareholdersApr 8, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 8, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 8, 2025Meeting noticeSEC
4 · Change in ownershipApr 4, 2025Insider tradeSEC
4 · Change in ownershipApr 4, 2025Insider tradeSEC
4 · Change in ownershipApr 4, 2025Insider tradeSEC
4 · Change in ownershipMar 31, 2025Insider tradeSEC
3 · Initial statement of ownershipMar 24, 2025Insider tradeSEC
S-8 · Registration statement for employee plansMar 13, 2025Offer documentSEC
POS AM · Amendment to an effective registrationMar 13, 2025Offer documentSEC
10-K · Annual reportMar 13, 2025Annual reportSEC
POSASRMar 13, 2025Other filingsSEC
8-K · Current reportMar 13, 2025ResultsSEC
8-K · Current reportMar 4, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 5, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 31, 2025Big-stake noticeSEC
4/A · Change in ownership, amendedJan 14, 2025Insider tradeSEC
8-K · Current reportJan 14, 2025Material contractSEC
SCHEDULE 13G · Big-stake noticeJan 8, 2025Big-stake noticeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
144 · Notice of proposed saleDec 30, 2024Other filingsSEC
424B5 · ProspectusDec 9, 2024Offer documentSEC
8-K · Current reportDec 9, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 6, 2024Quarterly reportSEC
8-K · Current reportNov 6, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedNov 4, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedOct 17, 2024Big-stake noticeSEC
4 · Change in ownershipOct 2, 2024Insider tradeSEC
4 · Change in ownershipSep 18, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 18, 2024Insider tradeSEC
8-K · Current reportSep 17, 2024Management or board changeSEC
4 · Change in ownershipSep 4, 2024Insider tradeSEC
4 · Change in ownershipAug 12, 2024Insider tradeSEC
4 · Change in ownershipAug 5, 2024Insider tradeSEC
4 · Change in ownershipAug 5, 2024Insider tradeSEC
4 · Change in ownershipAug 5, 2024Insider tradeSEC
4 · Change in ownershipAug 5, 2024Insider tradeSEC
4 · Change in ownershipAug 5, 2024Insider tradeSEC
8-K · Current reportAug 5, 2024Management or board changeSEC
144 · Notice of proposed saleAug 1, 2024Other filingsSEC
10-Q · Quarterly reportAug 1, 2024Quarterly reportSEC
8-K · Current reportAug 1, 2024ResultsSEC
4 · Change in ownershipJul 30, 2024Insider tradeSEC
4 · Change in ownershipJul 30, 2024Insider tradeSEC
144 · Notice of proposed saleJul 29, 2024Other filingsSEC
4 · Change in ownershipJul 26, 2024Insider tradeSEC
4 · Change in ownershipJul 18, 2024Insider tradeSEC
4 · Change in ownershipJul 3, 2024Insider tradeSEC
4 · Change in ownershipJul 3, 2024Insider tradeSEC
144 · Notice of proposed saleJul 1, 2024Other filingsSEC
8-K · Current reportJun 12, 2024Management or board changeSEC
4 · Change in ownershipJun 4, 2024Insider tradeSEC
4 · Change in ownershipJun 4, 2024Insider tradeSEC
4 · Change in ownershipJun 4, 2024Insider tradeSEC
4 · Change in ownershipJun 4, 2024Insider tradeSEC
4 · Change in ownershipJun 4, 2024Insider tradeSEC
4 · Change in ownershipJun 4, 2024Insider tradeSEC
4 · Change in ownershipJun 4, 2024Insider tradeSEC
4 · Change in ownershipJun 4, 2024Insider tradeSEC
8-K · Current reportJun 3, 2024Meeting outcomeSEC
4 · Change in ownershipMay 16, 2024Insider tradeSEC
144 · Notice of proposed saleMay 14, 2024Other filingsSEC
10-Q · Quarterly reportMay 8, 2024Quarterly reportSEC
8-K · Current reportMay 8, 2024ResultsSEC
4 · Change in ownershipApr 17, 2024Insider tradeSEC
ARS · Annual report to shareholdersApr 4, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 4, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 4, 2024Meeting noticeSEC
4 · Change in ownershipMar 21, 2024Insider tradeSEC
4 · Change in ownershipMar 18, 2024Insider tradeSEC
8-K · Current reportMar 11, 2024Current reportSEC
424B5 · ProspectusMar 8, 2024Offer documentSEC
4 · Change in ownershipMar 7, 2024Insider tradeSEC
FWP · Free writing prospectusMar 7, 2024Offer documentSEC
424B5 · ProspectusMar 6, 2024Offer documentSEC
144 · Notice of proposed saleMar 5, 2024Other filingsSEC
S-8 · Registration statement for employee plansFeb 27, 2024Offer documentSEC

This page holds 200 of 806 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Regenxbio Inc.’s releases · as of Oct 30, 2026

Common shares
66,122,600
Fully diluted
66,122,600

Fully diluted

LineSharesAs of
Common shares66,122,600Oct 30, 2026

Warrants and options

Lot
Warrants · US$14.92 · expiry not stated

Share count over time

CountShares
Oct 30, 202666,122,600

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
BlackRock7.68M11.6%US$57.8MSep 30, 2026
Vanguard5.62M8.5%US$42.4MSep 30, 2026
Redmile Group, LLC5.05M7.6%US$38MSep 30, 2026
JPMorgan3.56M5.4%US$26.5MSep 30, 2026
State Street3.15M4.8%US$23.7MSep 30, 2026
T. Rowe Price1.93M2.9%US$14.5MSep 30, 2026
Two Sigma1.9M2.9%US$14.3MSep 30, 2026
Morgan Stanley1.81M2.7%US$13.7MSep 30, 2026
Goldman Sachs1.68M2.5%US$12.7MSep 30, 2026
Geode Capital1.58M2.4%US$11.9MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
AQR Capital Management LLC1.37M2.1%US$10.3MSep 30, 2026
Integral Health Asset Management, LLC1.2M1.8%US$9.04MSep 30, 2026
Citadel1.11M1.7%US$8.37MSep 30, 2026
D. E. Shaw & Co., Inc.1.07M1.6%US$8.08MSep 30, 2026
Nuveen1.01M1.5%US$7.59MSep 30, 2026
Marshall Wace, LLP879K1.3%US$6.62MSep 30, 2026
Bank of America700K1.1%US$5.27MSep 30, 2026
Point72 Asset Management, L.P.668K1.0%US$5.03MSep 30, 2026
Rtw Investments, LP556K0.84%US$4.18MSep 30, 2026
Schwab539K0.81%US$4.06MSep 30, 2026
Northern Trust504K0.76%US$3.79MSep 30, 2026
Millennium503K0.76%US$3.79MSep 30, 2026
Stifel Financial Corp483K0.73%US$3.63MSep 30, 2026
Qube Research & Technologies Ltd470K0.71%US$3.54MSep 30, 2026
Hrt Financial LP459K0.69%US$3.46MSep 30, 2026
Hudson Bay Capital Management LP440K0.67%US$3.31MSep 30, 2026
Fidelity422K0.64%US$3.18MSep 30, 2026
Lazard Asset Management LLC372K0.56%US$2.8MSep 30, 2026
Seven Grand Managers, LLC350K0.53%US$2.64MSep 30, 2026
Quantinno Capital Management LP348K0.53%US$2.62MSep 30, 2026
Ghisallo Capital Management LLC333K0.50%US$2.51MSep 30, 2026
Trexquant Investment LP283K0.43%US$2.13MSep 30, 2026
GSK plc271K0.41%US$2.04MSep 30, 2026
Franklin Templeton267K0.40%US$2.06MSep 30, 2026
Dimensional259K0.39%US$1.95MSep 30, 2026
Susquehanna253K0.38%US$1.9MSep 30, 2026
UBS251K0.38%US$1.89MSep 30, 2026
TD230K0.35%US$1.71MSep 30, 2026
ArchPoint Investors217K0.33%US$1.63MSep 30, 2026
Corient Private Wealth LP216K0.33%US$1.63MSep 30, 2026
Capital Fund Management S.A.214K0.32%US$1.61MSep 30, 2026
DWS211K0.32%US$1.59MSep 30, 2026
Y-Intercept (Hong Kong) Ltd196K0.30%US$1.47MSep 30, 2026
BNY159K0.24%US$1.19MSep 30, 2026
Ameriprise158K0.24%US$1.19MSep 30, 2026
Invesco150K0.23%US$1.13MSep 30, 2026
Nomura149K0.23%US$1.12MSep 30, 2026
Acadian Asset Management LLC139K0.21%US$1.04MSep 30, 2026
Quadrature Capital Ltd137K0.21%US$1.04MSep 30, 2026
Manufacturers Life Insurance Company, The137K0.21%US$1.03MSep 30, 2026

This page holds 50 of 167 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF1.96M3.0%US$23.5MJun 30, 2026
Vanguard Total Stock Market Index Fund1.5M2.3%US$17.9MJun 30, 2026
iShares Russell 2000 ETF1.27M1.9%US$15.2MJun 30, 2026
Nuveen Quant Small Cap Equity Fund855K1.3%US$8.29MJul 31, 2026
JPMorgan Small Cap Growth Fund630K0.95%US$7.55MJun 30, 2026
Vanguard Extended Market Index Fund564K0.85%US$6.76MJun 30, 2026
Fidelity Small Cap Index Fund528K0.80%US$5.12MJul 31, 2026
Vanguard Strategic Small-Cap Equity Fund467K0.71%US$5.6MJun 30, 2026
iShares Russell 2000 Growth ETF378K0.57%US$4.53MJun 30, 2026
BlackRock Advantage Small Cap Core Fund340K0.51%US$2.38MMay 29, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
iShares Biotechnology ETF336K0.51%US$4.03MJun 30, 2026
Fidelity Enhanced Small Cap Core ETF323K0.49%US$3.87MJun 30, 2026
Vanguard Market Neutral Fund282K0.43%US$3.38MJun 30, 2026
Fidelity Extended Market Index Fund247K0.37%US$1.73MMay 31, 2026
Vanguard Russell 2000 Index Fund242K0.37%US$1.7MMay 31, 2026
Schwab U.S. Small-Cap ETF225K0.34%US$1.58MMay 31, 2026
BlackRock Health Sciences Opportunities Portfolio215K0.32%US$1.5MMay 29, 2026
JPMorgan Small Cap Blend Fund200K0.30%US$2.4MJun 30, 2026
Vanguard Explorer Fund186K0.28%US$1.8MJul 31, 2026
JPMorgan Small Cap Value Fund168K0.25%US$2.01MJun 30, 2026
Strategic Advisers U.S. Total Stock Fund150K0.23%US$1.05MMay 31, 2026
Nomura Healthcare Fund149K0.23%US$1.79MJun 30, 2026
Dimensional U.S. Core Equity 2 ETF145K0.22%US$1.41MJul 31, 2026
Vanguard Health Care Index Fund130K0.20%US$908KMay 31, 2026
Schwab Small-Cap Index Fund116K0.18%US$1.13MJul 31, 2026
JPMorgan U.S. Small Company Fund112K0.17%US$1.34MJun 30, 2026
U.S. Micro Cap Portfolio111K0.17%US$1.08MJul 31, 2026
Invesco RAFI US 1500 Small-Mid ETF106K0.16%US$1.02MJul 31, 2026
iShares Core S&P Total U.S. Stock Market ETF101K0.15%US$1.2MJun 30, 2026
Multi-Manager Small Cap Equity Strategies Fund99,8240.15%US$700KMay 31, 2026
U.S. Small Cap Portfolio98,0600.15%US$950KJul 31, 2026
Master Small Cap Index Series91,1920.14%US$1.09MJun 30, 2026
BlackRock Advantage Small Cap Growth Fund89,1870.13%US$1.07MJun 30, 2026
Fidelity Total Market Index Fund85,3000.13%US$598KMay 31, 2026
iShares Russell 2000 Value ETF73,4850.11%US$880KJun 30, 2026
MFS Blended Research Small Cap Equity Fund72,2840.11%US$507KMay 31, 2026
Fidelity Series Total Market Index Fund72,2730.11%US$507KMay 31, 2026
Direxion Daily S&P Biotech Bull 3X Shares66,5600.10%US$645KJul 31, 2026
Nuveen Small Cap Blend Index Fund64,2250.10%US$622KJul 31, 2026
BlackRock Advantage SMID Cap Fund, Inc.62,2120.09%US$745KJun 30, 2026
Vanguard Growth And Income Fund57,1010.09%US$684KJun 30, 2026
ALPS Medical Breakthroughs ETF53,2000.08%US$373KMay 31, 2026
EQ/2000 Managed Volatility Portfolio49,2110.07%US$590KJun 30, 2026
Diversified Equity Alpha Master Portfolio48,2260.07%US$578KJun 30, 2026
Virtus Biotech Clinical Trials Etf46,6700.07%US$452KJul 31, 2026
JPMorgan Small Cap Value Portfolio41,3250.06%US$495KJun 30, 2026
Fidelity Small Cap Growth Index Fund37,7310.06%US$452KJun 30, 2026
Vanguard Russell 2000 Value Index Fund37,7250.06%US$264KMay 31, 2026
Small Cap Value Fund34,2210.05%US$240KMay 31, 2026
Fidelity Nasdaq Composite Index Fund34,1880.05%US$240KMay 31, 2026

This page holds 50 of 171 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Ciongoli Gregory Austin
Director
Buy53,407USD 9.36US$500KAug 27, 2026
Ciongoli Gregory Austin
Director
Buy49,196USD 9.14US$450KAug 26, 2026
Pakola Steve
Officer: Chief Medical Officer
Sale2,161USD 13.64US$29,476Jul 2, 2026
Pakola Steve
Officer: Chief Medical Officer
Sale36,725USD 12.86US$472KJul 1, 2026
Pakola Steve
Officer: Chief Medical Officer
Sale19,608USD 11.04US$216KJun 29, 2026
Pakola Steve
Officer: Chief Medical Officer
Sale15,309USD 11.02US$169KMay 11, 2026

Big stakes

StakeStakeSharesDateFiling
Redmile Group, LLC9.90%5.06MJun 30, 2025Schedule 13G
BlackRock, Inc.7.30%3.68MMar 31, 2025Schedule 13G
JPMorgan Chase & Co5.30%3.56MSep 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Argeris N Karabelas
Other companies: Bausch Health Companies Inc. (Director · Jun 14, 2016 – Jun 24, 2022 · Past); Rocket Pharmaceuticals, Inc. (Director · Feb 17, 2015 – Jun 24, 2015 · Past); Human Genome Sciences Inc (Director · Apr 27, 2006 – Jul 30, 2012 · Past); Vanda Pharmaceuticals Inc. (Director · Apr 12, 2006 – Jun 16, 2011 · Past); Nitromed Inc (Director · Mar 20, 2006 – Apr 24, 2009 · Past)
Director · Since at least Sep 16, 2015
David Stump
Other companies: MacroGenics, Inc. (Director · Since at least Oct 9, 2013); Portola Pharmaceuticals Inc (Director · Sep 24, 2015 – Jul 2, 2020 · Past); Dendreon Corp (Director · Jun 2, 2010 – Jan 3, 2014 · Past); Sunesis Pharmaceuticals Inc (Director · Jun 18, 2009 – Jun 30, 2020 · Past); Human Genome Sciences Inc (Exec. Vice President · Mar 10, 2009 – Jul 30, 2012 · Past)
Independent Board Member · Since at least Oct 14, 2015
Camille D Samuels
Other companies: Unity Biotechnology Inc (Director · May 2, 2018 – Jun 21, 2024 · Past); Achaogen Inc (Director · Mar 11, 2014 – Mar 11, 2014 · Past); Kythera Biopharmaceuticals Inc (Director · Oct 10, 2012 – Oct 1, 2015 · Past); Paratek Pharmaceuticals Inc (Director · May 9, 2006 – Feb 2, 2011 · Past)
Director · Sep 16, 2015 – Jun 1, 2016 · Past
Greg Ciongoli
Other companies: Theravance Biopharma, Inc. (Director · Since at least Nov 4, 2026); Gossamer Bio, Inc. (Director · Since at least Sep 16, 2026); Zymeworks Inc. (Director · Since at least Jan 12, 2026); Atara Biotherapeutics, Inc. (Director · Since at least Sep 3, 2025)
Independent Board Member · Since at least Aug 25, 2026
Daniel Tassé
Other companies: DBV Technologies SA (Chief Executive Officer · Since at least Jan 1, 2021); Mallinckrodt Inc (Interim Pres-Hospital Business · May 1, 2015 – May 1, 2015 · Past); Bellerophon Therapeutics Inc (Director · Feb 13, 2015 – Jun 21, 2018 · Past)
Independent Board Member · Since at least Aug 15, 2016
Donald J Hayden Jr
Other companies: Theseus Pharmaceuticals Inc (Director · May 17, 2022 – Feb 14, 2024 · Past); Amicus Therapeutics Inc (Director · Jan 2, 2018 – Jun 7, 2018 · Past); Insmed Incorporated (Director · Nov 14, 2017 – Apr 9, 2019 · Past)
Director · Oct 11, 2017 – May 29, 2020 · Past
Edgar Engleman
Other companies: Bolt Biotherapeutics, Inc. (Director · Feb 4, 2021 – Nov 29, 2023 · Past); Soleno Therapeutics, Inc. (Director · Jul 6, 2017 – Feb 5, 2018 · Past); Eiger Biopharmaceuticals Inc (Director · Mar 22, 2016 – Apr 12, 2017 · Past)
Director · Sep 16, 2015 – Sep 22, 2015 · Past
Gregory Austin Ciongoli
Other companies: Gossamer Bio, Inc. (Director · Since at least Sep 16, 2026); Zymeworks Inc. (Director · Since at least Aug 10, 2025); Atara Biotherapeutics, Inc. (Director · Since at least Sep 3, 2024)
Director · Since at least Aug 25, 2026
Luke Beshar
Other companies: Protara Therapeutics, Inc. (Chairman · Since at least Jan 9, 2020); Omega Therapeutics Inc (Director · Jul 29, 2021 – Jun 7, 2023 · Past); Trillium Therapeutics Inc (Director · Jan 1, 2021 – Nov 17, 2021 · Past)
Director · Sep 16, 2015 – Jun 4, 2021 · Past
Daniel J. Abdun-Nabi
Other companies: Aptevo Therapeutics Inc. (President · Since at least Aug 1, 2016); Emergent BioSolutions Inc. (CEO, Director · Nov 14, 2006 – Mar 4, 2019 · Past)
Director · Aug 5, 2016 – Jun 4, 2021 · Past
All 29 people
PersonSeat
Mitchell Chan
Other companies: Avalo Therapeutics, Inc. (Director · Since at least Dec 1, 2021); Viela Bio Inc (Chief Financial Officer · Oct 2, 2019 – Mar 13, 2021 · Past)
CHIEF FINANCIAL OFFICER · Since at least Sep 16, 2024
Curran M. Simpson
Other companies: Human Genome Sciences Inc (Sr. VP, Operations · Mar 10, 2008 – Jul 30, 2012 · Past)
President and Chief Executive Officer, Board Member · Since at least Sep 16, 2015
Faraz Ali
Other companies: Tenaya Therapeutics, Inc. (Chief Executive Officer · Since at least Jul 29, 2021)
Chief Business Officer · Feb 29, 2016 – Jan 4, 2017 · Past
George Migausky
Other companies: Immunovant, Inc. (Director · Dec 1, 2023 – Apr 1, 2025 · Past)
Chairman of the Board · Since at least May 31, 2024
Jean Bennett
Other companies: Opus Genetics, Inc. (Director · Since at least Oct 22, 2024)
Director · Since at least Sep 3, 2021
Jennifer Zachary
Other companies: Merck & Company, Inc. (EVP, General Counsel · Since at least Apr 16, 2018)
Independent Board Member · Since at least Jun 3, 2022
Steve Pakola
Other companies: Whitehawk Therapeutics, Inc. (Chief Medical Officer · Mar 15, 2017 – Feb 15, 2019 · Past)
Chief Medical Officer · Since at least Apr 17, 2019
Alexandra GlucksmannIndependent Board Member · Since at least Jun 3, 2022
Allan FoxIndependent Board Member · Since at least Jun 2, 2026
Allan M FoxDirector · Since at least Sep 16, 2015
Craig MalzahnChief Technology Officer · Since at least Mar 13, 2025
Dana CormackCorporate Communications · Since at least Nov 3, 2026
Kenneth T MillsDirector · Since at least Sep 16, 2015
Marianne KreinerHead of People · Since at least Nov 4, 2026
Olivier DanosCHIEF SCIENTIFIC OFFICER · Since at least Mar 27, 2017
Patrick J. ChristmasCHIEF LEGAL OFFICER · Since at least Aug 18, 2016
Ram PalankiChief Commercial Officer · Since at least Mar 13, 2025
Steve PakolaCHIEF MEDICAL OFFICER · Since at least Sep 24, 2026
Vittal VasistaChief Financial Officer · Sep 16, 2015 – Mar 19, 2024 · Past

Open People

Log in to ask 6ix AI your own questions about Regenxbio Inc.